appConfigEntityId

bodyType

customContents

entityId

entityUuid

isVideo

articlePageQuery

article

articleSchemaContent

content

hooksArticlePageAdvertisementConfigArticle

hooksArticlePageFloatingButtonConfigArticle

appConfig

filter

json

liveArticle

Kyodo

Japan’s health ministry panel on Thursday approved the commercialisation of two regenerative medicine products prepared from iPS cells, the first of their kind in the world.
The two drugs, ReHeart developed by Cuorips, a start-up originating from the University of Osaka, and Amchepry by Sumitomo Pharma and Racthera, will be used for patients with severe heart failure stemming from ischemic cardiomyopathy and Parkinson’s disease, respectively.
“I am very happy to see the first big step towards its societal implementation, 20 years since it was announced,” said Shinya Yamanaka, director emeritus at Kyoto University’s Centre for iPS Cell Research and Application.
Induced pluripotent stem cells, or iPS, were generated by Yamanaka, who announced the generation of mouse iPS cells in 2006 and human iPS cells in 2007. He won the Nobel Prize in Physiology or Medicine in 2012.
With ReHeart, heart muscle sheets derived from human iPS cells are placed on the surface of the heart, where they promote the formation of new blood vessels underneath and help restore heart function.

Patients with severe heart disease are often given medicine to prevent deterioration and sometimes may have to undergo a heart transplant.
In a clinical trial, the heart muscle sheets were transplanted into eight patients. The trial showed reduced symptoms, such as exhaustion and heart palpitations, as well as improvements in heart function and physical fitness.
With Amchepry, human iPS cells are grown into “dopaminergic neural progenitor cells” and injected into the patient’s brain.
The cells were transplanted into seven patients in a clinical trial. Of the six assessed for efficacy, the transplanted cells produced dopamine, and some patients also showed improvement in motor symptoms.
Parkinson’s disease is a progressive neurodegenerative disease caused by a degeneration and loss of dopamine-producing brain cells, which can lead to a decrease in motor function.
The panel set an approval term of seven years, with the product set to roll out after discussions regarding price, insurance coverage and preparations for manufacturing and distribution.
The products were approved in a limited capacity as the clinical studies for both products were conducted on a small number of patients. If they are later deemed safe, the products can be fully utilised without restrictions.
Cuorips said it aims to start selling its product within this year.


US firm Waymo to launch robotaxi service in Singapore in 2028

How will rate increase in Japan affect capital flow in global financial markets?

A new Trump-Kim summit would be a nightmare for everyone but Pyongyang

Warning against Japan’s military build-up surfaces at Beijing Xiangshan conference

Japan

Japan approves world’s first regenerative medicines using iPS cells

A heart muscle sheet derived from human stem cells at the University of Osaka. Photo: Kyodo

Shinya Yamanaka announced the generation of human iPS in 2007. Photo: Wikipedia Commons

Naked intruder exposes gaps in Japan’s royal security: ‘enormous failure’

(From left) Japan’s Crown Prince Akishino, Crown Princess Kiko, Princess Kako, Prince Hisahito, Princess Nobuko and Princess Akiko attend the traditional new year’s greeting ceremony at the Imperial Palace in Tokyo on January 2. Photo: AFP

Japan’s Emperor Naruhito waves to the public during the traditional new year’s greeting ceremony at the Imperial Palace on January 2. Photo: AFP

Japan’s Princess Kako at the Nikkei Cultural Centre Association in Rio de Janeiro, Brazil, last year. She reportedly witnessed the commotion at the palace on January 2. Photo: AFP

Japan’s Takaichi steps back from Liancourt Rocks pledge in sign of softer line on South Korea

The Dokdo or Takeshima Islands. Photo: AP

Japan’s Prime Minister Sanae Takaichi. Photo: TNS

Visitors tour South Korea’s easternmost Dokdo islets, also known in Japan as Takeshima. Photo: EPA-EFE/Yonhap

Russia emerges as unlikely growth market for Japan tourism as China pulls back

Foreign tourists wearing Japanese traditional kimono clothes pose for a photograph near Sensoji temple at Asakusa district, a popular sightseeing spot in Tokyo. Photo: Reuters

Tourists visiting the main crossroads of the popular Shinsekai area of Osaka. Photo: AFP

What next for Okinawa’s anti-base alliance after Japan election loss?

Anti-base activists take part in a protest against the construction of a US military facility in Henoko in Nago, Japan’s Okinawa prefecture, in 2022. Photo: AFP

US military MV-22 Osprey tilt-rotor aircraft parked at US Marine Corps Air Station Futenma in Ginowan, Okinawa. Photo: Kyodo

People make payments in a supermarket in Okinawa. Voters’ preoccupations have shifted from opposition to the US bases to “practical concerns”, a recent article has suggested. Photo: Shutterstock

Why Takaichi’s Japan election victory has sparked North Korea’s ‘childish’ fury

Military personnel hold national flags of Japan and the US during a Japan Ground Self-Defence Force training at Camp Narashino, near Tokyo, on January 11. Photo: EPA

Plaintiffs, their lawyers and supporters gather outside the Tokyo District Court after it ordered North Korea to pay damages for luring Japanese to the North with false promises on January 26. Photo: AP

Defence ministers from Japan, Shinjiro Koizumi (left), and South Korea, Ahn Gyu-back, review the troops at the Japan Maritime Self-Defence Force headquarters on January 30. Photo: Reuters 

News

Asia

East Asia

Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson’s disease


Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson’s disease.


Japan approves world’s first regenerative medicines using iPS cells

.css-1c6uqr6{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;overflow-wrap:break-word;}Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson’s disease

Drugs made with iPS, or induced pluripotent stem cells, will be used to treat patients with severe heart failure and Parkinson’s disease